What Happened in the Stock Market Today

What Happened in the Stock Market Today

Stocks fell slightly on Wednesday, with both the Dow Jones Industrial Average (DJINDICES:^DJI) and the S&P 500 (SNPINDEX:^GSPC) indexes finishing the trading session lower by less than 0.30%. Today’s stock market: Index Percentage Change Point Change Dow (0.16%) (32.60) S&P 500 (0.25%) (5.58) Among the most popular exchange-traded funds, the Financial Select Sector SPDR Fund (NYSEMKT:XLF), → Read More

Why InvenSense, Twilio, and Navistar International Jumped Today

Why InvenSense, Twilio, and Navistar International Jumped Today

The stock market stalled out on Wednesday, with many investors focusing on the failure of the Dow Jones Industrials to cross the much-watched 20,000 mark. Losses among major market benchmarks were quite modest at a quarter percent or less, and the level of intraday volatility was minimal, pointing to the tug of war that traders → Read More

This Deal Is Another Reason to Take Lucid Motors Seriously

This Deal Is Another Reason to Take Lucid Motors Seriously

Silicon Valley electric-car start-up Lucid Motors said it has entered a “strategic supply agreement” with South Korean giant LG Chem (NASDAQOTH: LGCLF) for lithium-ion battery cells for Lucid’s upcoming electric luxury sedan, the Air. The news was something of a surprise, as it follows an announcement earlier this month of a similar deal between Lucid → Read More

Trump taps Carl Icahn for regulations busting post

Trump taps Carl Icahn for regulations busting post

Icahn: I’m against the stupidity of some regulations Donald Trump once suggested he wanted Carl Icahn to be his Treasury secretary. But with that job gone, he instead has tapped Icahn to serve as a special adviser on regulatory reform. Trump’s transition office said Wednesday that activist investor Icahn “will be a leader in helping → Read More

Online Discount Brokers: Capital One vs. Charles Schwab

Online Discount Brokers: Capital One vs. Charles Schwab

Long before online discount brokers brought Wall Street to your home through the internet, brokers gathered at a New York coffeehouse to make trades. It’s safe to say that things have gotten a lot better since the 1800s, but there are a few steps to making your first investment — for one, you’ll still need → Read More

Here's Why Merrimack Pharmaceuticals Tumbled 18.4% Today

Here's Why Merrimack Pharmaceuticals Tumbled 18.4% Today

What happened Shares of biopharma Merrimack Pharmaceuticals (NASDAQ:MACK) dropped 18.4% today after the company announced that it was stopping a phase 2 trial of a drug aimed at HER2-positive breast cancer. A panel of independent investigators determined that although the drug was safe, it was unlikely to outperform drugs already on the market for the → Read More

Mortgage Rates Hit New Highs, but That Isn't Stopping Homebuyers

Mortgage Rates Hit New Highs, but That Isn't Stopping Homebuyers

Fixed-rate mortgage rates were unchanged on Wednesday. The average 30-year mortgage rate is 4.16%, which equates to a $486.69 monthly payment per $100,000 borrowed. A month ago, the equivalent payment would have been lower by $11.58. The average 15-year mortgage is 3.32%, equating to a $706.08 monthly payment per $100,000 borrowed. A month ago, the → Read More

Amazon.com Inc.'s Voice-Controlled Speakers Are Holiday Hits

Amazon.com Inc.'s Voice-Controlled Speakers Are Holiday Hits

If you were thinking about buying one of Amazon.com‘s (NASDAQ:AMZN) new voice-activated speakers on the company’s website for a Christmas gift, it’s too late. Barring some in-store inventory at the company’s three bookstores, its 30 pop-up store locations at shopping malls, and some other bricks-and-mortar retailers, the Echo devices are completely sold out. The hot → Read More

Christmas Came Early for These Biotech Stocks

Christmas Came Early for These Biotech Stocks

The week before Christmas is typically a slow time of the year for news releases, a staple of biotech valuation changes. But Clovis Oncology (NASDAQ:CLVS), Akebia Therapeutics (NASDAQ:AKBA), Merus (NASDAQ: MRUS), and Ionis Pharmaceuticals (NASDAQ:IONS) all had news this week that sent their shares higher — an early present for investors. An accelerated accelerated approval → Read More

Trump forms new trade council to stop 'exodus of jobs'

Trump forms new trade council to stop 'exodus of jobs'

America’s complicated, critical trade relations with China President-elect Donald Trump has big plans to stop the “exodus of jobs” to China, Mexico and other countries. On Wednesday, Trump announced he is forming a new White House National Trade Council that has one goal: “To make American manufacturing great again.” Read More

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.